NCT04927897Recruiting
DETECT: Target Volume for Rectal Endoluminal Radiation Boosting
DETECT: Defining the Target Volume for Endoluminal Radiation Boosting in Patients With Rectal Cancer
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
The aim of the study is to provide prospective data regarding microscopic tumor spread in all directions from the macroscopic tumor in pathology specimens, as seen by eye, and on imaging to define the target volume for endoluminal radiation boosting in rectal cancer patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 9 Jun 2021
- Start date
- 16 Aug 2022
- Primary completion date
- May 2027
- Lead sponsor
- Maastricht Radiation Oncology
- Diseases
- Colorectal cancer
- NCT number
- NCT04927897
What you commit to
- Study type: Observational
- Planned participants: 50
- From 16 Aug 2022 to the primary completion date, May 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient has received brachytherapy as part of neoadjuvant treatment.
- Patient has not been treated with neoadjuvant radiotherapy or long-course chemoradiotherapy.
- Patient will not undergo TME surgery for a ycT1-3N0 residual histology confirmed rectal adenocarcinoma.
- Interval between end of neoadjuvant therapy and surgery is \<6 weeks.
Age
- \<18 years of age or incapable of giving informed consent.
Who the study is looking for
- ≥18 years of age and capable of giving informed consent.
- ycT1-3N0(\*) residual(\*\*) histology confirmed rectal adenocarcinoma after neoadjuvant radiotherapy or long-course chemoradiotherapy for which patients will undergo TME surgery.
- Minimal interval between end of neoadjuvant chemoradiotherapy or radiotherapy: 6 weeks.
- (\*)= as determined by clinical assessment (digital rectal examination, endoscopy with or without biopsy) and/or MRI. Biopsy/histology around the time of diagnosis is adequate; no biopsy/histology is needed after neoadjuvant therapy.
- (\*\*)= including tumor regrowths/local recurrence after an initial clinical complete response and a "watch and wait" approach. These patients will also be included after the local recurrence has been determined using endoscopy and/or MRI.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Catharina hospital Coordinator of this site? Confirm its status | Eindhoven | Netherlands | Recruiting |
| Maastro Coordinator of this site? Confirm its status | Maastricht | Netherlands | Recruiting |
| Maastricht University Medical Center Coordinator of this site? Confirm its status | Maastricht | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.